Evidence map›Paper›PMID 40321619›Full record

ArticleNeuro-oncology advances

Characterizing long- and short-survival glioblastoma patients with FLT-PET/MRI and metabolomics.

Jan Axelsson, Benny Björkblom, Thomas Asklund, Jens Brandel, Svante Larhed, Gabriela M Ringmar, Karolina Hedman, Katrine Riklund, Rickard L Sjöberg, Maria Sandström

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jan AxelssonDepartment of Diagnostics and Interventions, Radiation Physics, Umeå University, Umeå, Sweden.
Benny BjörkblomDepartment of Chemistry, Umeå University, Umeå, Sweden.ORCID https://orcid.org/0000-0001-9347-5790
Thomas AsklundDepartment of Diagnostics and Interventions, Oncology, Umeå University, Umeå, Sweden.
Jens BrandelDepartment of Diagnostics and Interventions, Diagnostic Radiology, Umeå University, Umeå, Sweden.
Svante LarhedDepartment of Diagnostics and Interventions, Oncology, Umeå University, Umeå, Sweden.
Gabriela M RingmarDepartment of Diagnostics and Interventions, Oncology, Umeå University, Umeå, Sweden.
Karolina HedmanDepartment of Surgical Sciences, Molecular Imaging and Medical Physics, Uppsala University, Uppsala, Sweden.
Katrine RiklundDepartment of Diagnostics and Interventions, Diagnostic Radiology, Umeå University, Umeå, Sweden.
Rickard L SjöbergDepartment of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden.
Maria SandströmDepartment of Diagnostics and Interventions, Oncology, Umeå University, Umeå, Sweden.ORCID https://orcid.org/0009-0002-4328-8561

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glioblastoma is the most aggressive and malignant brain tumor, characterized by a high degree of heterogeneity, invasiveness, and resistance to treatment. Patients with glioblastoma have a very poor prognosis despite multimodal interventions. In this study, we investigated how Methods: Patients, scheduled for surgery due to suspected high-grade glioma were included in this clinical study and underwent four Results: Both 2 and 6 weeks into treatment, short-time survivors displayed a significantly larger tumor volume than long-time survivors. When comparing MRI findings during treatment, long-time survivors displayed a substantial tumor decrease, whereas the short-time survivors showed minor or no effect. Regarding Conclusions: MRI measures of tumor volume and growth during treatment appear to be prognostic clinical factors that affect outcome. Metabolomic patterns in blood differ significantly between the defined survival groups and may serve as support for an early forecast of prognosis. We also observe a clear separation in metabolite levels between different time points during treatment, which likely reflects treatment effects.

Indexed as

glioblastomametabolomicsPETprognosis

Identifiers

PMID40321619
PMCPMC12048876

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.